

Dyfrig A Hughes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1555785/dyfrig-a-hughes-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

6,750
citations

42
h-index

76
g-index

245
ext. papers

8,109
ext. citations

4.8
avg, IF

6.11
L-index

#	Paper	IF	Citations
203	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 691-705	3.8	910
202	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 335-42		236
201	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 1637-1646	59.2	218
200	Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. <i>Drugs</i> , 2013 , 73, 545-62	12.1	214
199	Is exercise effective in promoting mental well-being in older age? A systematic review. <i>Aging and Mental Health</i> , 2010 , 14, 652-69	3.5	183
198	Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. <i>Value in Health</i> , 2015 , 18, 906-14	3.3	169
197	Drugs for exceptionally rare diseases: do they deserve special status for funding?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005 , 98, 829-36	2.7	141
196	ESCOMP Medication Adherence Reporting Guideline (EMERGE). <i>Annals of Internal Medicine</i> , 2018 , 169, 30-35	8	138
195	Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. <i>Health Economics (United Kingdom)</i> , 2013 , 22, 948-64	2.4	131
194	Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis. <i>BMJ, The</i> , 2007 , 334, 682	5.9	125
193	Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. <i>Journal of Advanced Nursing</i> , 2009 , 65, 706-23	3.1	124
192	The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 519	2.8	117
191	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. <i>BMJ, The</i> , 2011 , 343, d6333	5.9	117
190	The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. <i>Health Economics (United Kingdom)</i> , 2001 , 10, 601-15	2.4	116
189	Follow-up of cancer in primary care versus secondary care: systematic review. <i>British Journal of General Practice</i> , 2009 , 59, e234-47	1.6	105
188	Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. <i>Value in Health</i> , 2013 , 16, 863-71	3.3	102
187	Predicting adherence to medications using health psychology theories: a systematic review of 20 years of empirical research. <i>Value in Health</i> , 2014 , 17, 863-76	3.3	100

186	Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. <i>Value in Health</i> , 2012 , 15, 1162-71	3.3	100
185	Generic and therapeutic substitutions in the UK: are they a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 335-41	3.8	98
184	Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 265-74	6.1	96
183	Patients' and healthcare professionals' views of cancer follow-up: systematic review. <i>British Journal of General Practice</i> , 2009 , 59, e248-59	1.6	92
182	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. <i>Pharmacoeconomics</i> , 2016 , 34, 771-93	4.4	83
181	Non-compliance with antibiotic therapy for acute community infections: a global survey. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 245-53	14.3	83
180	Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. <i>Value in Health</i> , 2009 , 12, 915-22	3.3	81
179	Generic substitution: authors' response. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 968-968	3.8	78
178	Impregnated central venous catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1732-42	4.0	73
177	Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. <i>Value in Health</i> , 2007 , 10, 498-509	3.3	72
176	Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. <i>Value in Health</i> , 2010 , 13, 867-72	3.3	67
175	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). <i>Trials</i> , 2014 , 15, 14	2.8	64
174	Resource-use measurement based on patient recall: issues and challenges for economic evaluation. <i>Applied Health Economics and Health Policy</i> , 2013 , 11, 155-61	3.4	59
173	Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. <i>Lancet, The</i> , 2019 , 394, 1530-1539	4.0	58
172	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 66-76	3.8	57
171	Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 199-207	6.1	51
170	The development of a QALY measure for epilepsy: NEWQOL-6D. <i>Epilepsy and Behavior</i> , 2012 , 24, 36-43	3.2	51
169	Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. <i>Malaria Journal</i> , 2009 , 8, 204	3.6	51

168	Accounting for noncompliance in pharmacoeconomic evaluations. <i>Pharmacoeconomics</i> , 2001 , 19, 1185-97.	4.4	50
167	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 800-12	1.9	49
166	Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. <i>Value in Health</i> , 2012 , 15, 650-5	3.3	48
165	Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. <i>Value in Health</i> , 2015 , 18, 206-16	3.3	47
164	Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. <i>Epilepsia</i> , 2015 , 56, 556-63	6.4	46
163	Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity. <i>Annals of Behavioral Medicine</i> , 2014 , 48, 293-9	4.5	46
162	Understanding medication compliance and persistence from an economics perspective. <i>Value in Health</i> , 2008 , 11, 600-10	3.3	45
161	An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. <i>BMC Family Practice</i> , 2012 , 13, 30	2.6	41
160	Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure. <i>Health Economics (United Kingdom)</i> , 1995 , 4, 213-20	2.4	40
159	The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol. <i>Trials</i> , 2014 , 15, 4	2.8	39
158	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1375-1386	4.0	37
157	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. <i>Rheumatology</i> , 2017 , 56, 1729-1739	3.9	35
156	Defining rewardable innovation in drug therapy. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 253-4	64.1	35
155	Multiple imputation of multiple multi-item scales when a full imputation model is infeasible. <i>BMC Research Notes</i> , 2016 , 9, 45	2.3	33
154	A global survey of antibiotic leftovers in the outpatient setting. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 530-6	14.3	32
153	NICE and new: appraising innovation. <i>BMJ, The</i> , 2010 , 340, b5493	5.9	32
152	Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. <i>BMJ, The</i> , 2019 , 365, l1226	5.9	31
151	Pharmacogenetic tests: the need for a level playing field. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 3-4	64.1	30

150	Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity. <i>Pharmacoeconomics</i> , 2013 , 31, 345-55	4.4	29
149	Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 123-7	6.1	29
148	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1363-1374	4.0	29
147	Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey. <i>Value in Health</i> , 2018 , 21, 640-649	3.3	28
146	A framework for planning and critiquing medication compliance and persistence research using prospective study designs. <i>Clinical Therapeutics</i> , 2009 , 31, 421-35	3.5	28
145	Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study. <i>PLoS ONE</i> , 2016 , 11, e0164681	3.7	28
144	New drugs for old: disinvestment and NICE. <i>BMJ, The</i> , 2010 , 340, c572	5.9	27
143	Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. <i>Pharmacoeconomics</i> , 2016 , 34, 447-61	4.4	26
142	When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devices. <i>Pharmacoeconomics</i> , 2007 , 25, 621-35	4.4	26
141	Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial. <i>BMC Psychiatry</i> , 2007 , 7, 65	4.2	25
140	Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. <i>Pharmacoeconomics</i> , 2012 , 30, 779-94	4.4	23
139	Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 1-8	6.1	23
138	Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?. <i>Pharmacoeconomics</i> , 2001 , 19, 1069-77	4.4	23
137	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1149-59	3.8	22
136	The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE). <i>Healthcare (Switzerland)</i> , 2020 , 8,	3.4	22
135	Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care. <i>Clinical and Translational Science</i> , 2018 , 11, 450-460	4.9	22
134	Affordable orphan drugs: a role for not-for-profit organizations. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1595-1601	3.8	21
133	The difference between effectiveness and efficacy of antimalarial drugs in Kenya. <i>Tropical Medicine and International Health</i> , 2004 , 9, 967-74	2.3	21

132	Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 289-300	3.8	20
131	Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. <i>Pharmacoeconomics</i> , 2004 , 22, 1047-59	4.4	20
130	Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. <i>Drug Safety</i> , 2004 , 27, 535-54	5.1	20
129	Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation. <i>Health Technology Assessment</i> , 2014 , 18, vii-viii, 1-159	4.4	20
128	Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. <i>Value in Health</i> , 2017 , 20, 687-693	3.3	19
127	A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 829-37 ¹	6.1	19
126	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010 , 11, 989-1002	2.6	19
125	Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. <i>Health Technology Assessment</i> , 2017 , 21, 1-180	4.4	19
124	Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 269-76	6.1	18
123	Generalisability and Cost-Impact of Antibiotic-Impregnated Central Venous Catheters for Reducing Risk of Bloodstream Infection in Paediatric Intensive Care Units in England. <i>PLoS ONE</i> , 2016 , 11, e0151348	2.7	18
122	Opportunity costs and local health service spending decisions: a qualitative study from Wales. <i>BMC Health Services Research</i> , 2016 , 16, 103	2.9	17
121	Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma. <i>Pharmacoeconomics</i> , 2012 , 30, 413-29	4.4	17
120	Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. <i>Pharmacoeconomics</i> , 2005 , 23, 1031-41	4.4	17
119	Beyond registration--measuring the public-health potential of new treatments for malaria in Africa. <i>Lancet Infectious Diseases</i> , 2006 , 6, 46-52	25.5	17
118	Trends and influences on use of antidiabetic drugs in England, 1992-2003. <i>Pharmacoepidemiology and Drug Safety</i> , 2005 , 14, 769-73	2.6	17
117	Core Health Outcomes in Childhood Epilepsy (CHOICE): Development of a core outcome set using systematic review methods and a Delphi survey consensus. <i>Epilepsia</i> , 2019 , 60, 857-871	6.4	16
116	A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration. <i>Patient</i> , 2016 , 9, 281-92	3.7	16
115	Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods. <i>Value in Health</i> , 2018 , 21, 538-546	3.3	16

114	Taxonomy for methods of resource use measurement. <i>Health Economics (United Kingdom)</i> , 2015 , 24, 372-8	2.4	16
113	Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. <i>PLoS ONE</i> , 2017 , 12, e0172971	3.7	16
112	CATHeter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children. <i>Health Technology Assessment</i> , 2016 , 20, vii-xxviii, 1-219	4.4	16
111	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012 , 13, 1405-17	2.6	15
110	How many Epley manoeuvres are required to treat benign paroxysmal positional vertigo?. <i>Journal of Laryngology and Otology</i> , 2015 , 129, 421-4	1.8	14
109	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Ophthalmology</i> , 2019 , 126, 415-424	7.3	14
108	A systematic review of economic evaluations of advanced therapy medicinal products. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2428-2443	3.8	14
107	Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care. <i>Antibiotics</i> , 2018 , 7,	4.9	14
106	Biosimilars: evidential standards for health technology assessment. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 257-61	6.1	13
105	Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-112	4.4	13
104	Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 672-683	6.1	13
103	Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales. <i>Sexually Transmitted Infections</i> , 2021 , 97, 85-87	2.8	13
102	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. <i>Epilepsy and Behavior</i> , 2014 , 36, 12-7	3.2	12
101	Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015 , 370,	5.8	12
100	Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. <i>Pharmacogenomics</i> , 2013 , 14, 151-63	2.6	12
99	Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1429-1438	6.1	12
98	Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. <i>Epilepsy and Behavior</i> , 2015 , 45, 180-6	3.2	11
97	Abolition of prescription copayments in Wales: an observational study on dispensing rates. <i>Value in Health</i> , 2010 , 13, 675-80	3.3	11

96	The problem of orphan drugs. <i>BMJ, The</i> , 2010 , 341, c6456	5.9	11
95	Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam. <i>British Journal of Pharmacology</i> , 2020 , 177, 4975-4989	8.6	10
94	Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 142-152	3.8	10
93	Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 871-8	3.8	10
92	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-140	4.4	10
91	A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomic Working Group of the European Network on ME/CFS (EUROMENE). <i>Medicina (Lithuania)</i> , 2020 , 57,	3.1	10
90	Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. <i>Value in Health</i> , 2021 , 24, 539-547	3.3	10
89	Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set. <i>Trials</i> , 2017 , 18, 572	2.8	9
88	Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 749-751	6.1	9
87	The New and Non-Transparent Cancer Drugs Fund. <i>Pharmacoeconomics</i> , 2020 , 38, 1-4	4.4	9
86	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 978-996	6.1	8
85	Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. <i>Value in Health</i> , 2018 , 21, 1373-1381	3.3	8
84	Health Utilities and Costs for Motor Neurone Disease. <i>Value in Health</i> , 2019 , 22, 1257-1265	3.3	8
83	Pharmacoeconomics. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 968-72	3.8	8
82	Economic impact of poor compliance with pharmaceuticals. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2002 , 2, 327-35	2.2	8
81	What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 522-31	3.8	8
80	Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections. <i>Trials</i> , 2015 , 16, 163	2.8	7
79	Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions. <i>International Journal of Pharmacy Practice</i> , 2015 , 23, 333-9	1.7	7

78	Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay. <i>International Journal of Pharmacy Practice</i> , 2010 , 18, 332-40	1.7	7
77	Silver-impregnated, antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent shunt infection: the BASICS three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-114	4.4	7
76	Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. <i>Wiener Klinische Wochenschrift</i> , 2015 , 127, 379-84	2.3	6
75	New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. <i>Pharmacoeconomics</i> , 2018 , 36, 613-624	4.4	6
74	Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. <i>Value in Health</i> , 2018 , 21, 1322-1329	3.3	6
73	A systematic review and empirical analysis of the relation between dose and duration of drug action. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 17-26	2.9	6
72	Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. <i>Pharmacoeconomics</i> , 2009 , 27, 635-43	4.4	6
71	Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire. <i>Quality of Life Research</i> , 2007 , 16, 1419-23	3.7	6
70	Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. <i>Lancet Rheumatology, The</i> , 2021 , 3, e347-e356	14.2	6
69	Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE). <i>European Journal of Cardiovascular Nursing</i> , 2019 , 18, 258-259	3.3	6
68	Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. <i>Pharmacoeconomics</i> , 2017 , 35, 397-413	4.4	5
67	Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance. <i>Antibiotics</i> , 2019 , 8,	4.9	5
66	What really matters? A mixed methods study of treatment preferences and priorities among people with epilepsy in the UK. <i>Epilepsy and Behavior</i> , 2019 , 95, 181-191	3.2	5
65	Patient compliance with drug therapy for diabetic nephropathy. <i>Cmaj</i> , 2000 , 162, 1553-4	3.5	5
64	Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol. <i>BMJ Open</i> , 2019 , 9, e033504	3	5
63	Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia. <i>Australian Health Review</i> , 2019 , 43, 254-260	1.8	5
62	What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 251-260	2.8	5
61	Acceptability of generic versus innovator oral medicines: not only a matter of taste. <i>Drug Discovery Today</i> , 2021 , 26, 329-343	8.8	5

60	Perceptions of European ME/CFS Experts Concerning Knowledge and Understanding of ME/CFS among Primary Care Physicians in Europe: A Report from the European ME/CFS Research Network (EUROMENE). <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	5
59	CARer-ADministration of as-needed subcutaneous medication for breakthrough symptoms in homebased dying patients (CARIAD): study protocol for a UK-based open randomised pilot trial. <i>Trials</i> , 2019 , 20, 105	2.8	4
58	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , 2019 , 37, 1509-1523	4.4	4
57	Cost-effectiveness of HLA-B*15:02 screening in Malaysia. <i>British Journal of Dermatology</i> , 2017 , 177, 904-905	4.05	4
56	Ring-fencing a budget for cancer drugs: is it fair?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2011 , 41, 224-8	0.9	4
55	Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. <i>Clinical Medicine</i> , 2009 , 9, 490-2	1.9	4
54	NHS and charitable funding for children and young people with cancer in England and Wales. <i>Journal of Child Health Care</i> , 2008 , 12, 156-68	2	4
53	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). <i>BMJ Open</i> , 2020 , 10, e040635	3	4
52	Nerve root block versus surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial. <i>Trials</i> , 2018 , 19, 475	2.8	4
51	Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers. <i>Medical Decision Making</i> , 2019 , 39, 910-925	2.5	3
50	Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 652-660	6.1	3
49	Rare disease prevention and treatment: the need for a level playing field. <i>Pharmacogenomics</i> , 2018 , 19, 243-247	2.6	3
48	Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review. <i>Thorax</i> , 2017 ,	7.3	3
47	A randomised, patient-assessor blinded, sham-controlled trial of external non-invasive peripheral nerve stimulation for chronic neuropathic pain following peripheral nerve injury (EN-PENS trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 574	2.8	3
46	Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. <i>Frontiers in Pharmacology</i> , 2017 , 8, 644	5.6	3
45	A Fully Integrated Real-Time Detection, Diagnosis, and Control of Community Diarrheal Disease Clusters and Outbreaks (the INTEGRATE Project): Protocol for an Enhanced Surveillance System. <i>JMIR Research Protocols</i> , 2019 , 8, e13941	2	3
44	Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARIAD feasibility RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-150	4.4	3
43	Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 49-63	6.1	3

42	Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational CollaborateProject. <i>BMJ Open</i> , 2019 , 9, e031696	3.6	3
41	Managing access to advanced therapy medicinal products: Challenges for NHS Wales. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2444-2449	3.8	3
40	Medicines Shortages in the United Kingdom. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 712	6.1	2
39	HTAs and rare diseases: How to assess their cost-effectiveness. <i>Pharmaceuticals Policy and Law</i> , 2011 , 13, 161-165		2
38	Orphan drugs revisited: author's response. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006 , 99, 350-351	2.7	2
37	Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005 , 5, 29-38	2.2	2
36	PMDP4: THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES. <i>Value in Health</i> , 2000 , 3, 373	3.3	2
35	Seizure first aid training for people with epilepsy attending emergency departments and their significant others: the SAFE intervention and feasibility RCT. <i>Health Services and Delivery Research</i> , 2020 , 8, 1-190	1.5	2
34	TEOS: A framework for constructing operational definitions of medication adherence based on Timelines-Events-Objectives-Sources. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2521-2533	3.8	2
33	Health utilities and costs for neuromyelitis optica spectrum disorder.. <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 159	4.2	2
32	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.. <i>Health Technology Assessment</i> , 2021 , 25, 1-134	4.4	2
31	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. <i>Journal of Personalized Medicine</i> , 2019 , 9,	3.6	1
30	Renal transplant patients' preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment. <i>BMC Nephrology</i> , 2017 , 18, 305	2.7	1
29	Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. <i>Health Economics (United Kingdom)</i> , 2018 , 27, 236-243	2.4	1
28	Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC). <i>Trials</i> , 2018 , 19, 408	2.8	1
27	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , 2018 , 129, 1104-1105	3.2	1
26	New advice on switching antiepileptic drugs might be a false economy. <i>BMJ, The</i> , 2013 , 347, f7471	5.9	1
25	Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14967	2.9	1

24	Management of Patients Symptomatically Unresponsive to Levothyroxine: Natural Desiccated Thyroid Extract or the Combination of Levothyroxine and Liothyronine? A Research Priority. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020 , 128, 596-598	2.3	1
23	Impact of Relaxing Covid-19 Social Distancing Measures on Rural North Wales: A Simulation Analysis. <i>Frontiers in Public Health</i> , 2020 , 8, 562473	6	1
22	The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE). <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
21	Cost-effectiveness of home versus hospital management of children at onset of type 1 diabetes: the DECIDE randomised controlled trial. <i>BMJ Open</i> , 2021 , 11, e043523	3	1
20	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
19	Prof. John Urquhart. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 573	3.8	1
18	Seizure First Aid Training For people with Epilepsy (SAFE) frequently attending emergency departments and their significant others: results of a UK multi-centre randomised controlled pilot trial. <i>BMJ Open</i> , 2020 , 10, e035516	3	1
17	Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. <i>Pharmacoeconomics</i> , 2021 , 39, 25-61	4.4	1
16	Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 75-83	4.5	1
15	Mechanistically informed non-invasive peripheral nerve stimulation for peripheral neuropathic pain: a randomised double-blind sham-controlled trial. <i>Journal of Translational Medicine</i> , 2021 , 19, 458	8.5	0
14	Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis. <i>BMJ Open</i> , 2021 , 11, e051702	3	0
13	Microdiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-86	4.4	0
12	Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. <i>Trials</i> , 2021 , 22, 429	2.8	0
11	NICE recommendations: why no disinvestment recommendations to offset investment decisions?. <i>BMJ, The</i> , 2015 , 350, h2656	5.9	
10	Drug utilization research and pharmacoeconomics 2016 , 425-432		
9	062 Abolition of prescription co-payments in Wales: an observational study on dispensing rates. <i>Journal of Epidemiology and Community Health</i> , 2010 , 64, A25-A25	5.1	
8	Medicines concordance and game theory. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 577	3.8	
7	Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: pharmacoeconomic considerations. <i>European Journal of Cancer</i> , 2005 , 41, 1655; author reply 1656-7	7.5	

6	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial.. <i>JMIR Research Protocols</i> , 2022 , 11, e32918	2
5	Health Technology Assessment (HTA) for Smaller Countries: The role of the health economist. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY11-3	0
4	Reply. <i>Ophthalmology</i> , 2019 , 126, e24-e25	7.3
3	Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project. <i>Trials</i> , 2021 , 22, 68	2.8
2	EstablishING the best STEp-up treatments for children with uncontrolled asthma despite INhaled corticosteroids (EINSTEIN): protocol for a systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data (IPD). <i>BMJ Open</i> , 2021 , 11, e040528	3
1	Plasma Methylmalonic Acid Concentration in Folic Acid-Supplemented Depressed Patients with Low or Marginal Vitamin B-12: A Randomized Trial. <i>Journal of Nutrition</i> , 2021 , 151, 3738-3745	4.1